Page last updated: 2024-11-13
6-hydroxywarfarin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
6-hydroxywarfarin: metabolite of (R)-warfarin; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 54682459 |
| CHEMBL ID | 148730 |
| SCHEMBL ID | 1478281 |
| MeSH ID | M0051658 |
Synonyms (33)
| Synonym |
|---|
| warfarin-alcohol |
| NCGC00165929-01 |
| CHEMBL148730 |
| 6-hydroxywarfarin |
| SCHEMBL1478281 |
| A812359 |
| 17834-02-5 |
| 2,6-dihydroxy-3-(3-oxo-1-phenyl-butyl)chromen-4-one |
| 4,6-dihydroxy-3-(3-oxo-1-phenylbutyl)-2h-1-benzopyran-2-one |
| p25d26m0hk , |
| unii-p25d26m0hk |
| 6-hydroxy warfarin |
| FT-0637611 |
| 2h-1-benzopyran-2-one,4,6-dihydroxy-3-(3-oxo-1-phenylbutyl)- |
| 6-hydroxywarfarin, (rs)- |
| 6-hydroxywarfarin, (+/-)- |
| JFCOGWFGPAUYNK-UHFFFAOYSA-N |
| 3-(.alpha.-acetonylbenzyl)-4,6-dihydroxycoumarin |
| 2h-1-benzopyran-2-one, 4,6-dihydroxy-3-(3-oxo-1-phenylbutyl)- |
| AKOS030239603 |
| J-011369 |
| 6-monohydroxywarfarin |
| (r)-6-hydroxy warfarin |
| (s)-6-hydroxy warfarin |
| FT-0670233 |
| 4,6-dihydroxy-3-(3-oxo-1-phenylbutyl)-2h-chromen-2-one |
| 2,6-dihydroxy-3-(3-oxo-1-phenylbutyl)-4h-1-benzopyran-4-one |
| DTXSID50939073 |
| Q27286027 |
| 6-hydroxywarfarin-d5 |
| 4,6-dihydroxy-3-(3-oxo-1-phenylbutyl)chromen-2-one |
| PD039352 |
| AKOS040755432 |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| "To develop population pharmacokinetic models of both R- and S-warfarin using clinical and genetic factors and to identify the covariates which influence the interindividual variability in the pharmacokinetic parameters of clearance and volume of distribution in patients on long-term warfarin therapy." | ( The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors. Aarons, L; Al-Zubiedi, S; Daly, AK; Deloukas, P; Hatch, E; Hughes, D; Jorgensen, AL; Kamali, F; Lane, S; Matthews, I; Ogungbenro, K; Park, BK; Pirmohamed, M, 2012) | 0.38 |
| " A base pharmacokinetic model was developed using NONMEM software to determine the warfarin clearance and volume of distribution." | ( The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors. Aarons, L; Al-Zubiedi, S; Daly, AK; Deloukas, P; Hatch, E; Hughes, D; Jorgensen, AL; Kamali, F; Lane, S; Matthews, I; Ogungbenro, K; Park, BK; Pirmohamed, M, 2012) | 0.38 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| "Warfarin is a drug with a narrow therapeutic index and large interindividual variability in daily dosing requirements." | ( The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors. Aarons, L; Al-Zubiedi, S; Daly, AK; Deloukas, P; Hatch, E; Hughes, D; Jorgensen, AL; Kamali, F; Lane, S; Matthews, I; Ogungbenro, K; Park, BK; Pirmohamed, M, 2012) | 0.38 |
| "Our analysis, based on exposure rather than dose, provides quantitative estimates of the clinical and genetic factors impacting on the clearance of both the S- and R-enantiomers of warfarin, which can be used in developing improved dosing algorithms." | ( The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors. Aarons, L; Al-Zubiedi, S; Daly, AK; Deloukas, P; Hatch, E; Hughes, D; Jorgensen, AL; Kamali, F; Lane, S; Matthews, I; Ogungbenro, K; Park, BK; Pirmohamed, M, 2012) | 0.38 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (1)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 50.1187 | 0.1413 | 37.9142 | 100.0000 | AID1490 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Bioassays (7)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID293981 | Inhibition of rat microsomal VKER | 2007 | Bioorganic & medicinal chemistry, Mar-15, Volume: 15, Issue:6 | Synthesis and structure-activity relationships of novel warfarin derivatives. |
| AID16339 | Amount of deuterium retained was reported after normal workup in beta-naphthoflavone-treated male rats with the substrate rac 7-D | 1985 | Journal of medicinal chemistry, Aug, Volume: 28, Issue:8 | Substrate probes for the mechanism of aromatic hydroxylation catalyzed by cytochrome P-450: selectively deuterated analogues of warfarin. |
| AID16344 | Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup | 1985 | Journal of medicinal chemistry, Aug, Volume: 28, Issue:8 | Substrate probes for the mechanism of aromatic hydroxylation catalyzed by cytochrome P-450: selectively deuterated analogues of warfarin. |
| AID16342 | Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats with rac 8-D | 1985 | Journal of medicinal chemistry, Aug, Volume: 28, Issue:8 | Substrate probes for the mechanism of aromatic hydroxylation catalyzed by cytochrome P-450: selectively deuterated analogues of warfarin. |
| AID16341 | Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats | 1985 | Journal of medicinal chemistry, Aug, Volume: 28, Issue:8 | Substrate probes for the mechanism of aromatic hydroxylation catalyzed by cytochrome P-450: selectively deuterated analogues of warfarin. |
| AID16340 | Amount of deuterium retained was reported after normal workup in rats | 1985 | Journal of medicinal chemistry, Aug, Volume: 28, Issue:8 | Substrate probes for the mechanism of aromatic hydroxylation catalyzed by cytochrome P-450: selectively deuterated analogues of warfarin. |
| AID16345 | Compound incubated with microsomal preparations from phenobarbital treated male rats with the substrate rac 8-D and the amount of deuterium retained was reported after normal workup | 1985 | Journal of medicinal chemistry, Aug, Volume: 28, Issue:8 | Substrate probes for the mechanism of aromatic hydroxylation catalyzed by cytochrome P-450: selectively deuterated analogues of warfarin. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (12)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (16.67) | 18.7374 |
| 1990's | 3 (25.00) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.94
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.94) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 13 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||